The RAC 3-Pillar Trifecta, page-6

great analysis - appreciate the time and effort! Very invaluable for existing shareholders and those coming onboard. also did my own independent number crunching / DD rather than just relying blindly on hotcopper posts. everything appears conservative and in line with biotech valuation methods, couldn't fault it. obviously there are various assumptions and risks in relation to trials and commercial success, which there is no way around unless you have a crystal ball. execution of the 5-path + 3 pillar strategy is therefore crucial over the next 12-18 months in particular. so far running lean, on time and gathering momentum for next trials. looking forward to 2021!

When i find the time i will do an analysis of the share price and market cap history. think a lot of potential investors may be put off by a $2+ price when they look and others like PNV in the $3+ range. In comparison this is like getting into PNV at $0.30 given the number of shares issued by the respective companies.

held from IPO and looking to see this through to buyout. this would generate significant profits but most importantly provide a treatment option for cancer - which would be priceless!